AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17599421 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-brain magnetic resonance imaging
Number of subjects: 2977
Study 15699477 — intervention group
Group type: EXPERIMENTAL
Intervention: gefitinib 250 mg/d
Number of subjects: 216
Study 15699477 — intervention group
Group type: EXPERIMENTAL
Intervention: gefitinib 500 mg/d
Number of subjects: 216
Study 11969355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (breast screening intervention program delivered by lay health educators)
Number of subjects: 325
Study 11969355 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 325
Study 11969355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (with significant others providing information/help)
Number of subjects: 325
Study 11969355 — intervention group
Group type: COMPARATOR
Intervention: Control group (with significant others providing information/help)
Number of subjects: 325
Study 9032097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin therapy (IP)
Number of subjects: 22
Study 9032097 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 22
Study 9032097 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 22
Study 7822993 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on diagnostic tests, chart audit, and feedback provided twice a week for first and second year residents; peer-review strategy for staff.
Number of subjects: 36
Study 7822993 — intervention group
Group type: COMPARATOR
Intervention: Control group (R2C)
Number of subjects: 36
Study 3555162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg epinephrine added to hyperbaric spinal bupivacaine
Number of subjects: 63
Study 3555162 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric spinal bupivacaine without epinephrine
Number of subjects: 63
Study 29318430 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-T MRI in cPM/cICD carriers (study group, SG)
Number of subjects: 120
Study 29318430 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiac MRI in cPM/cICD carriers (study group, SG)
Number of subjects: 120
Study 29318430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI in cPM carriers (study group, SG)
Number of subjects: 120
Study 29318430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI in cICD carriers (study group, SG)
Number of subjects: 120
Study 29318430 — intervention group
Group type: COMPARATOR
Intervention: Chest x-ray, CT or follow-up (reference group, RG)
Number of subjects: 120
Study 27857633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 31
Study 27857633 — intervention group
Group type: COMPARATOR
Intervention: Ischemic Compression (IC)
Number of subjects: 31
Study 25135124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of oral melatonin administered at 9:00 pm for four consecutive days
Number of subjects: 198
Study 25135124 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 9:00 pm for four consecutive days
Number of subjects: 198
Study 25135124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of oral melatonin
Number of subjects: 198
Study 22994519 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 23
Study 22994519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22994519 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (HA) exposure
Number of subjects: 23
Study 19933916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (3 or 4 cycles)
Number of subjects: 1867
Study 18812366 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation of a non‐polluting, more effective home heater
Number of subjects: 409
Study 16157231 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 8
Study 16157231 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (0 and 600 mg/day)
Number of subjects: 8
Study 12147851 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular irradiation with a (192)Ir source (14 Gy 2 mm deep to the vessel wall)
Number of subjects: 30
Study 12147851 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (control group)
Number of subjects: 30
Study 10436249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 217
Study 10436249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 10436249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 217
Study 7749088 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with extreme T2 weighting (TR 5950 ms, TE 150 ms)
Number of subjects: 49
Study 7749088 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with T2 weighting
Number of subjects: 49
Study 7749088 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantifying a grey scale to demonstrate early marrow oedema
Number of subjects: 49
Study 1932484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (10 mg bolus followed by a constant infusion of 3.2 mg/h)
Number of subjects: 20
Study 1932484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similarly administered)
Number of subjects: 20
Study 7136659 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed human milk for all feeds
Number of subjects: 261
Study 7136659 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk for half the feeds and nursery formula for the rest
Number of subjects: 261
Study 7136659 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum, 20 ml three times a day along with nursery formula
Number of subjects: 261
Study 7136659 — intervention group
Group type: COMPARATOR
Intervention: Nursery formula only
Number of subjects: 261
Study 30430667 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation therapy for 20 min and oral health education for 15 min before periodontal treatment once per week for 4 wk
Number of subjects: 68
Study 30430667 — intervention group
Group type: COMPARATOR
Intervention: Oral health education only for the same duration
Number of subjects: 68
Study 30430667 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation therapy
Number of subjects: 68
Study 30430667 — intervention group
Group type: COMPARATOR
Intervention: Oral health education only
Number of subjects: 68
Study 29933364 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 63
Study 29933364 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 63
Study 29933364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26898569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine modified-release tablets (MR group, n = 123)
Number of subjects: 251
Study 26898569 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine enteric-coated tablets (EC group, n = 128)
Number of subjects: 251
Study 26898569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine modified-release tablets (MR group)
Number of subjects: 251
Study 26898569 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine enteric-coated tablets (EC group)
Number of subjects: 251
Study 24808486 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dairy condition (+4 servings conventional nonfat dairy products/d)
Number of subjects: 49
Study 24808486 — intervention group
Group type: COMPARATOR
Intervention: No-dairy condition (+4 servings fruit products/d)
Number of subjects: 49
Study 23034968 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrAA (6.77 g of a mixture of 5 essential amino acids 3 times/d)
Number of subjects: 9
Study 23034968 — intervention group
Group type: COMPARATOR
Intervention: HFr (3 g fructose · kg(‐1) · d(‐1) and maltodextrin placebo 3 times/d)
Number of subjects: 9
Study 19444662 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy MOMS (stress-reduction and social support intervention)
Number of subjects: 0
Study 19444662 — intervention group
Group type: COMPARATOR
Intervention: Parenting Skills for MOMS (parenting skills intervention)
Number of subjects: 0
Study 17623344 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalized quasi-likelihood (PQL)
Number of subjects: 0
Study 17623344 — intervention group
Group type: COMPARATOR
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0
Study 17623344 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed variance estimator from PQL
Number of subjects: 0
Study 15015000 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cooling with a warm core of 39.5 degrees C
Number of subjects: 20
Study 15015000 — intervention group
Group type: COMPARATOR
Intervention: Passive warming to rectal temperature of 39.5 degrees C
Number of subjects: 20
Study 11606169 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (blood glucose approximately 6 mmol/l)
Number of subjects: 16
Study 11606169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose approximately 14 mmol/l)
Number of subjects: 16
Study 9875586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (14-session face-to-face HIV risk-reduction intervention emphasizing abstinence and safer sexual practices)
Number of subjects: 515
Study 9875586 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 515
Study 8033186 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml Oolong tea extract (OTE) solution in 0.2% ethanol before and after every intake of food and before sleeping at night
Number of subjects: 35
Study 8033186 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ethanol without OTE for mouthrinsing
Number of subjects: 35
Study 8033186 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml Oolong tea extract (OTE) solution
Number of subjects: 35
Study 2756357 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin (administered preoperatively as a single bolus infusion)
Number of subjects: 168
Study 2756357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered preoperatively as a single bolus infusion)
Number of subjects: 168
Study 791330 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (average daily dose about 600 mg)
Number of subjects: 19
Study 791330 — intervention group
Group type: COMPARATOR
Intervention: labetalol
Number of subjects: 19
Study 31448635 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone coaching
Number of subjects: 0
Study 31448635 — intervention group
Group type: COMPARATOR
Intervention: Self-study
Number of subjects: 0
Study 31448635 — intervention group
Group type: COMPARATOR
Intervention: Group coaching
Number of subjects: 0
Study 31482360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD)
Number of subjects: 205
Study 31482360 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet (CLD)
Number of subjects: 205
Study 31395306 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 140
Study 31395306 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 140
Study 31395306 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 140
Study 31395306 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 140
Study 28151543 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 8240
Study 28151543 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 8240
Study 25579875 — intervention group
Group type: EXPERIMENTAL
Intervention: Donning devices with CS40-o-t
Number of subjects: 40
Study 25579875 — intervention group
Group type: EXPERIMENTAL
Intervention: Donning devices with CS40-c-t
Number of subjects: 40
Study 25579875 — intervention group
Group type: EXPERIMENTAL
Intervention: Donning devices with CS20+20-o-t
Number of subjects: 40
Study 25579875 — intervention group
Group type: EXPERIMENTAL
Intervention: Donning devices with CS20+20-c-t
Number of subjects: 40
Study 25579875 — intervention group
Group type: COMPARATOR
Intervention: Without donning devices with CS40-c-t
Number of subjects: 40
Study 25579875 — intervention group
Group type: COMPARATOR
Intervention: Without donning devices with CS20+20-c-t
Number of subjects: 40
Study 23944206 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma filtration
Number of subjects: 48
Study 23944206 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 48
Study 21592324 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted program conducted by a mobile geriatric team including geriatric preoperative consultation, training of surgical staff, implementation of the Hospital Elder Life Program, and morbidity and mortality conference related to delirium cases.
Number of subjects: 360
Study 21592324 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 360
Study 18473792 — intervention group
Group type: EXPERIMENTAL
Intervention: DG17 with sodium bicarbonate solution
Number of subjects: 6
Study 18473792 — intervention group
Group type: EXPERIMENTAL
Intervention: DG17 with low-dose ritonavir
Number of subjects: 6
Study 18473792 — intervention group
Group type: COMPARATOR
Intervention: DG17 without ritonavir
Number of subjects: 6
Study 17194247 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-velocity training (SVT) at 30 degrees .s(‐1)
Number of subjects: 30
Study 17194247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-velocity training (FVT) at 270 degrees .s(‐1)
Number of subjects: 30
Study 17194247 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 14738208 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (100 microg/m3 PM10) for 2 hours
Number of subjects: 0
Study 14738208 — intervention group
Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 0
Study 14738208 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (100 microg/m3 PM10) for 2 hours in subjects with asthma
Number of subjects: 0
Study 10793595 — intervention group
Group type: COMPARATOR
Intervention: PhysioFlex group (closed system)
Number of subjects: 16
Study 10793595 — intervention group
Group type: COMPARATOR
Intervention: Modulus group (low-flow system)
Number of subjects: 16
Study 10793595 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 16
Study 8746333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate
Number of subjects: 0
Study 8746333 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride
Number of subjects: 0
Study 8746333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanoic acid
Number of subjects: 0
Study 8746333 — intervention group
Group type: COMPARATOR
Intervention: Transepidermal water loss
Number of subjects: 0
Study 1384898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic/G-CSF mobilization
Number of subjects: 68
Study 1384898 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic mobilization
Number of subjects: 68
Study 3909332 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin (AV)
Number of subjects: 170
Study 3909332 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin and amikacin (AVA)
Number of subjects: 170
Study 3909332 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam plus ticarcillin (MT)
Number of subjects: 170
Study 31026084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 0
Study 31026084 — intervention group
Group type: COMPARATOR
Intervention: Ipragliflozin in T2DM patients with moderate renal impairment
Number of subjects: 0
Study 29389579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankascin 568 plus (500 mg/day)
Number of subjects: 40
Study 29389579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26995799 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35 mg
Number of subjects: 428
Study 26995799 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 18 mg
Number of subjects: 428
Study 26995799 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg loading dose followed by 200 mg twice daily
Number of subjects: 428
Study 26995799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 23970645 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyactin A for 3 months
Number of subjects: 48
Study 23970645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 22892735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL 1% peracetic acid (PAA)
Number of subjects: 48
Study 22892735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL 17% EDTA
Number of subjects: 48
Study 22892735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL 2.5% NaOCl + 2.5 mL 17% EDTA
Number of subjects: 48
Study 22892735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL 0.5% PAA
Number of subjects: 48
Study 22892735 — intervention group
Group type: COMPARATOR
Intervention: Positive control group
Number of subjects: 48
Study 22892735 — intervention group
Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 48
Study 20424084 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-game system immediately
Number of subjects: 0
Study 20424084 — intervention group
Group type: COMPARATOR
Intervention: Control group (video-game system after follow-up assessment)
Number of subjects: 0
Study 18460399 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth brushing alone
Number of subjects: 19
Study 18460399 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth brushing plus tongue scraping
Number of subjects: 19
Study 18460399 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth brushing plus tongue cleaning using a high speed vacuum ejector and irrigation with 20 ml antibacterial mouthwash
Number of subjects: 19
Study 18460399 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tongue scraping
Number of subjects: 19
Study 15798323 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization method applied to coronary angiograms
Number of subjects: 41
Study 12451982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet Tongmaijiangzhi (TTMJZ) 4 tablets, tid for 8 weeks
Number of subjects: 65
Study 12451982 — intervention group
Group type: COMPARATOR
Intervention: Zocor 5 mg, qd for 8 weeks
Number of subjects: 65
Study 10613415 — intervention group
Group type: EXPERIMENTAL
Intervention: 117 mg/day of vitamin C during repletion phase
Number of subjects: 68
Study 10613415 — intervention group
Group type: COMPARATOR
Intervention: 9 mg/day of vitamin C during depletion phase
Number of subjects: 68
Study 10613415 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight as a factor
Number of subjects: 68
Study 10613415 — intervention group
Group type: EXPERIMENTAL
Intervention: First repletion phase
Number of subjects: 68
Study 7655259 — intervention group
Group type: EXPERIMENTAL
Intervention: HNE Huntleigh's Vaperm pressure-reducing cushion
Number of subjects: 0
Study 7655259 — intervention group
Group type: EXPERIMENTAL
Intervention: HNE Huntleigh's Multitec pressure-reducing cushion
Number of subjects: 0
Study 7655259 — intervention group
Group type: EXPERIMENTAL
Intervention: HNE Huntleigh's Supatec pressure-reducing cushion
Number of subjects: 0
Study 1936788 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 0
Study 1936788 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study 7081116 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet (49.67 mg tin daily)
Number of subjects: 8
Study 7081116 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.11 mg tin daily)
Number of subjects: 8
Study 30256710 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 28
Study 30256710 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic simulation tasks
Number of subjects: 28
Study 28092012 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedically supported case management
Number of subjects: 46
Study 28092012 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare
Number of subjects: 46
Study 25608520 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance program (10-week duration)
Number of subjects: 100
Study 25608520 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study 24093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented visual feedback balance training
Number of subjects: 0
Study 24093506 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training according to physical therapy guidelines
Number of subjects: 0
Study 21134035 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote assessment using a novel optical imaging system with a three-dimensional camera and disposable optical marker.
Number of subjects: 20
Study 21134035 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment by clinicians.
Number of subjects: 20
Study 19929994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro mix 25 (LM25)
Number of subjects: 480
Study 19929994 — intervention group
Group type: COMPARATOR
Intervention: Glargine
Number of subjects: 480
Study 16955767 — intervention group
Group type: EXPERIMENTAL
Intervention: Betnesol nasal drops in Mygind's position
Number of subjects: 23
Study 16955767 — intervention group
Group type: COMPARATOR
Intervention: Betnesol nasal drops in LSHD position
Number of subjects: 23
Study 16955767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positions (Mygind's and LSHD)
Number of subjects: 23
Study 15026295 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence tracked with electronic cap monitors for 24 weeks
Number of subjects: 0
Study 15026295 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness and estimated IQ
Number of subjects: 0
Study 15026295 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and anxiety, mental flexibility, and visuospatial-constructional ability
Number of subjects: 0
Study 10770980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber group (13.5 g per day of wheat-bran fiber)
Number of subjects: 1303
Study 10770980 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber group (2 g per day of wheat-bran fiber)
Number of subjects: 1303
Study 10770980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber group
Number of subjects: 1303